![]() |
市場調查報告書
商品編碼
1727113
血管通路設備的全球市場:各產品類型,各用途,各終端用戶,各地區,機會,預測,2018年~2032年Vascular Access Devices Market Assessment, By Product Type, By Application, By End-user, By Region, Opportunities and Forecast, 2018-2032F |
全球血管通路器械市場規模預計將從2024年的63.3億美元成長到2032年的100.6億美元,在2025-2032年的預測期內,複合年增長率為5.94%。市場成長的動力源自於需要妥善治療的慢性病和傳染病的增加。此外,住院患者數量的增加以及對醫療基礎設施改善的日益重視,預計也將推動市場在預測期內以驚人的速度擴張。癌症等慢性病盛行率的上升,推動了對用於食物、液體和藥物傳遞的血管通路器械的需求。美國癌症協會估計,2025年美國將新增超過200萬例癌症病例。
血管通路裝置是用來將藥物、液體、血液和營養物質輸送到血管中的器械。這些器械包括經由周邊置入中心靜脈導管 (PICC)、中心靜脈導管、植入式輸液港、週邊靜脈導管 (PIVC) 等。隨著醫療服務和醫療設備的不斷發展,血管通路裝置在設計、材料和影像技術整合方面也不斷改進。血管通路裝置的進步提高了其生物相容性、靈活性以及新材料的採用,從而改善了患者的預後和生活品質。生活方式相關疾病負擔的增加、技術進步以及對微創手術的需求推動了對血管通路裝置的需求不斷增長。製造商始終致力於改進器械設計和材料,以改善患者預後並減少併發症。
此外,Teleflex Incorporated 於 2024 年 5 月推出了 Arrow EZ-IO 骨內通路操作托盤,增強了其骨內血管通路產品組合。 EZ-IO 採用首款經 FDA 批准的電池供電驅動器,可在無菌環境下使用,並包含骨內通路所需的所有組件。此托盤設計用於快速且準確地插入,解決了臨床醫生在緊急情況下建立血管通路所面臨的課題。然而,長期使用導管相關的風險,例如感染和敗血症,可能會對市場成長構成課題。
本報告提供全球血管通路設備市場相關調查,提供市場概要,以及各產品類型,各用途,各終端用戶,各地區趨勢,及加入此市場的主要企業簡介等資訊。
Global vascular access devices market is projected to witness a CAGR of 5.94% during the forecast period 2025-2032, growing from USD 6.33 billion in 2024 to USD 10.06 billion in 2032. The market's growth can be attributed to the rise in chronic diseases cases, and infections, among other disorders that require proper treatment. Additionally, rising hospitalizations and growing emphasis on improving healthcare infrastructure are further anticipated to support the market's expansion at a notable pace during the forecast period. The increasing prevalence of chronic diseases such as cancer is propelling the requirement for vascular access devices for administration of food, fluid, and medications. The American Cancer Society estimates that over 2 million new cancer cases will be reported in the United States in 2025.
Vascular access devices are insertions used to administer drugs, fluids, blood, and nutrients in blood vessels. These devices include peripherally inserted central catheters (PICCs), central venous catheters, implantable ports, and peripheral intravenous catheters (PIVCs). With the never-ending evolution of healthcare services and medical devices, vascular access devices have evolved in terms of design, material, and integration of imaging technologies in it. Advancements in vascular access devices have improved biocompatibility, flexibility, and the adoption of novel materials, enhancing patient outcomes and quality of life. The rising demand for vascular access devices is driven by the growing burden of lifestyle diseases, technological advancements, and the need for minimally invasive procedures. Manufacturers are consistently working to enhance device design and materials to improve patient outcomes and reduce complications.
Moreover, in May 2024, Teleflex Incorporated launched the Arrow EZ-IO Intraosseous Access Procedure Tray, enhancing its intraosseous vascular access portfolio. It includes all necessary components for intraosseous access, featuring the first FDA-cleared battery-powered driver that can be utilized in sterile environments. The tray is designed for quick and precise insertion, addressing the challenges clinicians face in obtaining vascular access during emergencies. However, risks associated with long-term use of catheters, such as infections and sepsis may pose challenges for market growth.
Rising Burden of Chronic Diseases to Drive the Market Growth
The chronic disease burden is on a rise globally, owing to the increasing prevalence of chronic diseases, such as cancer, cardiovascular and urological disorders, and others, which necessitates frequent and long-term vascular access for treatments such as chemotherapy, dialysis, and medication administration, thereby driving the demand for various types of vascular access devices, including central venous catheters and peripheral IV catheters. Another factor contributing to the growing burden is the rising geriatric population, highly prone to catching such diseases. With the ongoing scenario, the future demand for vascular access devices is anticipated to increase further.
For instance, the National Institute of Health (NIH), anticipates that the number of adults 50 years and older suffer from at least one chronic disease, which will increase by 99.5% from 71.522 million in 2020 to 142.66 million in 2050. An estimated 48 million people, or 47% of all deaths globally, are expected to die from severe health-related suffering by 2060, an 87% increase from 26 million in 2016. It is anticipated that 83% of these deaths will occur in low and middle-income countries. As per World Health Organization (WHO) estimates, by 2050, there will be twice as many people 60 years or older on the planet with the population of 2.1 billion.
Design Improvements and Advancements to Drive Market Demand
The established types of vascular access devices include central venous catheters (CVCs), arteriovenous fistulas (AVFs), and arteriovenous grafts (AVGs). Innovations in CVC tip and coating design have improved patency and blood flow rates. AVFs are preferred over CVCs as they are less prone to clotting and infection while providing reliable and adequate blood flow rates. With such design enhancements, the AVF creation devices have significant traction leading to market growth. Market players are taking chances to launch innovative products with enhanced designs. For instance, in September 2023, Laminate Medical Technologies announced that it received US-FDA clearance for its VasQ External Vascular Support device, designed to create AVFs for dialysis access. Notably, 80% of patients in trials using VasQ were able to remove central venous catheters within their first year of treatment, reducing the risk of infection compared to traditional AVFs. The VasQ device provides structural reinforcement to the vessels during AVF creation, promoting better arterial flow and functionality.
Similarly, in May 2023, Teleflex launched the Arrow VPS Rhythm DLX Device and NaviCurve Stylet in the United States, aiming to enhance peripherally inserted central catheter (PICC) insertion procedures and reduce complications. The VPS Rhythm DLX Device provides real-time catheter tip location by utilizing the patient's cardiac electrical activity, eliminating the need for confirmatory X-rays. It also offers an optional integrated ultrasound with a Catheter-to-Vessel ratio tool to standardize vessel measurement. In benchtop testing, the NaviCurve Stylet achieved a 90% success rate in first-attempt PICC placement into the lower third of the SVC, compared to a 0% success rate with a leading competitor. These innovations reflect Teleflex's commitment to reducing catheter-related complications.
Rise in the Number of Surgeries and Hospital Admissions to Further Fuel
The increase in the number of surgeries and hospital admissions is another major factor driving the growth of the vascular access devices market. The rising requirement for surgical intervention is propelling the reliance on vascular access devices for post-surgical monitoring, fluid management, and perioperative care, among others. In order to meet the evolving requirements of the healthcare professionals and the patient population, leading medical device companies are focusing in innovations and technological advancements to ensure the availability of efficient and safe devices, including products with microbial coatings to reduce device failure because of infections, smart catheters, and minimally invasive systems. Hospitals across the globe are focusing on adopting next-generation solutions to minimize risks and improve treatment outcomes.
As more patients are admitted for effective management and treatment of chronic diseases, including diabetes, cancer, chronic kidney diseases, and cardiovascular diseases, the requirement for effective and reliable vascular access devices is increasing for administering intravenous therapies, medications, chemotherapy, and dialysis, among others. Moreover, the reliance on surgical intervention is also increasing due to the increasing complexities of various medical conditions, thus augmenting the demand for vascular access devices for food and fluid administration.
Drug Administration Application to Dominate Vascular Access Devices Market Share
The drug administration application of the vascular access devices market is anticipated to cover the highest market share. As these devices provide reliable, long-term access to the bloodstream, which is essential for patients needing frequent or prolonged intravenous therapies, such as chemotherapy or chronic disease management, reducing complications associated with traditional IV lines, such as infections and vein irritation, by minimizing the need for repeated needle sticks. A recent study published in the British Medical Journal in July 2024 examined the effectiveness of vascular access devices (VADs) in reducing infection rates among hospitalized patients. The study concluded that VADs along with specific safety measures reduce the chances of infection.
North America Dominates the Global Vascular Access Devices Market Share
North America is anticipated to hold major market share of the global vascular access devices market. North America's leadership in the demand for vascular access devices is attributed to its advanced healthcare infrastructure, rising prevalence of chronic diseases, technological innovations, supportive regulations, and demographic trends favoring increased healthcare needs. According to the United States Renal Data System 2023 Annual Data Report, more than 85% of individuals who began hemodialysis used a catheter. Additionally, nearly three-quarters of the United States population started without permanent access, a significant increase from about 65% in 2018. This rise in number clearly shows an increasing consumption of such devices in North America causing it to hold the largest market share among other regions.
Future Market Scenario (2025-2032F)
The vascular access devices market has witnessed several remarkable futuristic advancements that are anticipated to shape the future of such devices. These advancements include wearable technology, remote monitoring of atrioventricular flow, use of biocompatible materials for product design, 3D printing technology, image-guided vascular access devices, and others. The USFDA approval of WavelinQ and Ellipsys, two vascular access devices that facilitate the creation of arteriovenous fistulas (AVFs) using minimally invasive techniques has paved a new path for more products in line with endovascular fistula creation. One of the most revolutionary advancement is the image-guided vascular access system, Ultreon 1.0 was launched by Abbott in October 2023. This platform uses near-infrared light to provide high-definition, precise imaging from within the blood vessels, allowing healthcare professionals precise access to blood vessels even in the most complex anatomies.
Similarly, in October 2024, Medtronic received FDA approval for its Affera Mapping and Ablation System, integrated with the Sphere-9 Catheter, marking a significant advancement in electrophysiology. This system offers physicians a comprehensive solution for the treatment of cardiac arrhythmias by combining high-density mapping and focal ablation capabilities into a single catheter. The Sphere-9 Catheter is designed to streamline procedures by reducing the need for multiple devices, thereby enhancing procedural efficiency and patient outcomes. The system's intuitive interface and real-time data integration facilitate precise navigation and targeted therapy delivery. This FDA approval underscores Medtronic's commitment to innovation in cardiac care, providing clinicians with advanced tools to effectively manage complex arrhythmias.
Impact of the U.S. Tariffs
The recent imposition of tariffs of medical devices and related components is expected to have a significant impact on the market as they are affecting imports from leading manufacturing hubs including Canada, China, and Mexico. The tariffs are also resulting in supply chain disruptions, rising production costs, and strategic shifts within the industry. The imposition of 25% tariffs on imported medical devices, including those made of aluminum and steel, are propelling the manufacturing expenses for vascular access devices. This is going to pose various challenges in the availability and affordability of implantable ports and central venous catheters as these devices heavily rely on precision engineering and specialized materials.
Manufacturers across the globe are compelled to re-evaluate their supply chains, relocating production to potentially limit the impact of the tariffs and seeking alternative suppliers. However, such changes can be both time-consuming and economically draining, resulting in increased operational complexities and delays in product availability. Moreover, shifting manufacturing locations and suppliers will also necessitate the reapplication for all the permits and approvals so that the materials and devices meet the various regulatory requirements posed by governing bodies such as the FDA.
Key Players Landscape and Outlook
The key players in the market are significantly investing in the development of vascular access devices and are utilizing strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing large-cap industry players to increase their presence and, therefore, find new opportunities in this market.
In November 2023, Becton Dickinson and Company launched the SiteRite 9 Ultrasound System, which is an advanced vascular access ultrasound designed to enhance clinician efficiency in placing peripherally inserted central catheters (PICCs), central venous catheters, and IV lines. SiteRite 9 aims to increase first-attempt insertion success and reduce unnecessary needlesticks, supporting BD's vision of a One-Stick Hospital Stay. The system received 510(k) Clearances in September 2023 and is available in the United States market.
In June 2023, Merit Medical, Inc. announced two strategic acquisitions totalling USD 132.5 million to enhance its dialysis catheter portfolio. Merit Medical is acquiring dialysis catheters and a sealant system from AngioDynamics, Inc. for USD 100 million, which complements its biopsy devices by preventing pneumothorax during lung biopsies. Additionally, Merit is purchasing the Surfacer catheter system from Bluegrass Vascular Technologies for USD 32.5 million, which facilitates central venous access.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.